Creoptix AG closes CHF 3 Million Series A Financing21.11.2013 06:10
Creoptix AG, a company developing analytical instruments for highly-sensitive label-free molecular interaction analysis, today announced the closing of a CHF 3 Million Series A round. The round was lead by business angels from StartAngels Network Zurich and joined by the cantonal banks of Aargau (AKB) and Zurich (ZKB) as well as several private investors.
With the financing round Eduard Brunner and Winfried Mayer, both representing StartAngels Network, and Jon Andri Jörg as independent member joined the board. Brunner will serve as chairman of the board.
Kaspar Cottier, founder and CTO of Creoptix AG, said: “Thanks to a grant from CTI/KTI we have been advancing our instrument in the last two years from a prototype to a product ready for the market. We are very happy with this perfectly timed financing round, which now allows us to proceed with the market introduction, and bringing the company to the next level.”
Matyas Vegh, CEO of Creoptix AG, said: “We are excited about the closing of this financing round, as well as the opportunities which are now opening up. We can now focus on satisfying our customers’ needs for high quality products. Our goal is to become the premium supplier for label-free devices within the next five years.”
About Creoptix AG
Creoptix AG is a privately-held company focused on the development of next generation instruments for the high-sensitivity analysis of label-free molecular interactions based on a innovative, proprietary technology called Grating-Coupled Interferometry (GCI). Creoptix’ instruments are characterized by very high sensitivity while still being robust and customer-friendly. The main applications for its instruments are in the drug discovery industry and for life-science and materials research. Creoptix was founded in 2009.